Welcome to our dedicated page for Liveworld news (Ticker: LVWD), a resource for investors and traders seeking the latest updates and insights on Liveworld stock.
LiveWorld, Inc. (OTC Markets: LVWD) is a social-first digital agency and software company that regularly publishes detailed business and financial updates. The LVWD news feed features company-issued announcements that explain how LiveWorld combines social media engagement, compliance, and insight solutions with software and AI, with a particular focus on healthcare and pharmaceutical brands.
Investors and observers following LVWD news will find recurring quarterly and annual financial results, including condensed balance sheets, statements of operations, and cash flow statements. These releases highlight revenue trends, operating expenses, net income or loss, and cash and cash equivalents, providing insight into how LiveWorld’s social-first and AI-focused strategy aligns with its financial performance.
Beyond earnings, LiveWorld’s news includes updates on its AI initiatives, such as an AI strategic roadmap, increased investment in AI enablement across the agency, and the launch of AI-powered products. The company has announced AI Brand Reputation Indexes for pharmaceutical and over-the-counter consumer healthcare brands, describing how large language models and AI platforms shape brand perception.
Additional LVWD news items cover developments in healthcare and pharma marketing, new solution sets in areas like compliance support for digital and social media, and changes to the company’s board of directors that are tied to its AI and healthcare growth strategy. For anyone researching LiveWorld’s evolving role in social media–driven customer relationships, this news page offers a centralized view of the company’s financial disclosures, strategic direction, and AI-related projects.
LiveWorld (OTC: LVWD) reported 2025 results: $11.1M total revenue, down ~2% year-over-year, and $326K net income (3% margin), a ~376% increase versus 2024. Cash and cash equivalents were $7.313M, with net cash available for operations of $5.7M.
Management said LiveWorld increased AI investment, launched new AI solutions, and is cautiously optimistic 2026 revenues will exceed 2025 based on current bookings.
LiveWorld (OTC: LVWD) launched an integrated GEO, AIO & SEO search optimization service on March 3, 2026 to help healthcare and regulated brands manage visibility, accuracy, and authority as search shifts toward AI-generated answers.
The solution combines audits, prompt/keyword intelligence, and AI-optimized content with human review to reduce misrepresentation and compliance risk in AI-driven discovery.
LiveWorld (OTC: LVWD) unveiled a Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap on January 21, 2026, introducing seven AI solutions for healthcare marketing. The roadmap blends decades of human-reviewed conversation data, regulatory expertise, and platform engineering to deliver AI that prioritizes safety, governance, and empathy.
Available now: AI Brand Reputation Reports and a new AI Chatbot Moderation service; three additional AI web-management tools and a human-led intelligence product are slated for Q1 2026, and a learning/discovery solution for Q2 2026. Company cites top-10 pharma clients using its AI today.
LiveWorld (OTC: LVWD) reported Q3 2025 results on November 13, 2025: Total revenue $2.84M (healthcare revenue $2.6M) and net income $195K for the quarter. Q3 revenue declined ~9% versus Q3 2024 and nine-month revenue was $8.07M versus $8.49M a year earlier. The company ended Q3 with $7.69M cash and cash equivalents and defined net cash available for operations of $6.0M. Deferred revenue and current liabilities rose materially versus year-end 2024. Management reiterated continued investments in AI and product development while noting market uncertainty and potential impacts on future earnings.
LiveWorld (OTC:LVWD) reported Q2 2025 financial results with total revenues of $2.7 million, down 5% year-over-year. The company posted a net loss of $92,000, a 31% improvement from Q2 2024's loss of $134,000. Healthcare revenues reached $2.4 million in Q2 2025.
The company's cash position strengthened to $5.5 million, up $729,000 from June 30, 2024. LiveWorld continues to invest heavily in AI across three areas: business operations, client solutions, and next-generation AI software products. Management noted that client spending remains cautious due to current market conditions, expecting this trend to persist.
Additionally, LiveWorld's creative digital marketing campaign for Chiesi Global Rare Diseases was named a finalist in the 2025 MM+M Awards for the Organic Social Media category.
LiveWorld (OTC:LVWD) has released the first-ever AI Brand Reputation Index for over-the-counter (OTC) consumer healthcare brands. The study analyzes how artificial intelligence platforms like ChatGPT influence the reputation of the top 50 OTC brands across ten product categories.
According to the report, CeraVe ranked as the leading brand, followed by Neutrogena, Advil, Nature Made, and Pepto-Bismol. The analysis was conducted using major AI models including ChatGPT-4, Claude, and Perplexity AI, evaluating brands across four key reputation drivers: product satisfaction, brand trust, visibility & marketing strength, and accessibility & value.
Key findings revealed that AI visibility significantly drives consumer preference, with top performers combining high consumer trust and perceived effectiveness. The study also found that natural and heritage brand storylines resonate strongly with AI platforms, while brands with low AI footprint missed significant opportunities despite their market presence.
LiveWorld (OTC: LVWD) reported its Q1 2025 financial results with total revenues remaining flat at $2.6 million compared to Q1 2024. The company's healthcare segment contributed $2.3 million in revenue. The net loss from operations improved by 45% to $276,000 compared to $498,000 in Q1 2024.
The company's cash position decreased by $1.6 million to $5.0 million, primarily due to timing issues with contract renewals. Accounts receivable significantly increased from $682,000 to $2.3 million. LiveWorld launched its first dedicated AI product, the AI Pharma Brand Reputation Index, in Q1 and plans to release more AI products in beta later this year as part of its increased investment in artificial intelligence initiatives.
LiveWorld (OTC: LVWD) has unveiled its first AI Brand Reputation Index, analyzing how artificial intelligence influences perceptions of 50 leading pharmaceutical brands. The study, released on April 15, 2025, employs LiveWorld's proprietary AI framework to evaluate seven weighted reputation factors across major language models including ChatGPT, Perplexity, and Grok.
The index revealed that established brands like Dupixent and Keytruda maintain strong AI reputations due to clinical effectiveness and healthcare professional trust. Notably, Vertex Pharmaceuticals' Trikafta topped the rankings despite advertising, while newer therapies like Leqvio and Rybrevant struggle with AI visibility. The study also highlighted how safety concerns impact AI-driven reputation for products like Remicade and Xeljanz.
The assessment factors included:
- Efficacy
- Safety
- Healthcare professional trust
- Consumer sentiment
- Digital visibility
- Affordability
- Patient loyalty
LiveWorld (LVWD) has reported its financial results for 2024, showing total revenues of $11.3 million, a 1% decrease from 2023. The company's healthcare segment generated $10.2 million in revenue. Despite market challenges, LiveWorld achieved a net income of $69,000, down from $214,000 in 2023.
The company's cash position strengthened significantly, with net cash increasing by $1.6 million to $6.2 million at year-end. LiveWorld has developed an AI strategic roadmap and is increasing investments in AI solutions, integrating human expertise with machine learning and analytics.
Management anticipates continued market uncertainty in 2025 and warns that ongoing investments may result in losses. However, they expect their AI-human intelligence blend to drive medium and long-term revenue growth.
LiveWorld (OTC: LVWD), a social-first digital agency focusing on healthcare and pharma brands, has appointed Carl Gustin to its Board of Directors. Gustin, currently Chief Strategy & Marketing Officer at SpeciCare, brings extensive experience in healthcare, technology, and AI-driven business transformation.
Gustin's background includes notable positions as Chief Marketing Officer at Kodak, where he led digital transformation efforts, and involvement in launching Apple's first PowerBook. He has been recognized as an Ad Age Top 50 Marketer.
The appointment aligns with LiveWorld's strategy to enhance its AI-driven solutions and expand its presence in the healthcare sector. The company, with 28 years of experience in digital engagement, aims to strengthen its position in pharmaceutical and healthcare marketing through innovative and compliant social media strategies.